These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 26891913

  • 1. Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma.
    Li M, Fu C, Zhang W, Huang W, Wang Z, Zhou T, Lin H, Li B.
    Br J Radiol; 2016; 89(1060):20150476. PubMed ID: 26891913
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma.
    Li BS, Gong HY, Huang W, Yi Y, Zhang ZC, Li HS, Wang ZT, Yu JM.
    Dis Esophagus; 2011 May; 24(4):251-7. PubMed ID: 21073623
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed and cisplatin for locally advanced oesophageal squamous cell carcinoma.
    Fu C, Li B, Guo L, Li H, Huang W, Gong H, Sun M, Wang Z, Zhou T, Liu C.
    Br J Radiol; 2014 May; 87(1037):20130656. PubMed ID: 24666012
    [Abstract] [Full Text] [Related]

  • 4. Concurrent Selective Lymph Node Radiotherapy and S-1 Plus Cisplatin for Esophageal Squamous Cell Carcinoma: A Phase II Study.
    Wang X, Liu X, Li D, Wang X, Huang W, Li B.
    Ann Surg Oncol; 2019 Jun; 26(6):1886-1892. PubMed ID: 30805810
    [Abstract] [Full Text] [Related]

  • 5. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
    Chen J, Su T, Lin Y, Wang B, Li J, Pan J, Chen C.
    Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
    [Abstract] [Full Text] [Related]

  • 6. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
    Cheng N, Liu Y, Zhao G, Xu Y, Zhang T, Chen Y, Yan G, Hu Y, Yao S, Wang Z, Wang C, Chen Z, Hu Z, Liu D, Chen T.
    Int J Radiat Oncol Biol Phys; 2020 Feb 01; 106(2):340-348. PubMed ID: 31655197
    [Abstract] [Full Text] [Related]

  • 7. Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: a phase III randomized study.
    Zhao KL, Shi XH, Jiang GL, Yao WQ, Guo XM, Wu GD, Zhu LX.
    Int J Radiat Oncol Biol Phys; 2005 Jul 15; 62(4):1014-20. PubMed ID: 15990003
    [Abstract] [Full Text] [Related]

  • 8. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J, Kato K, Ito Y, Kojima T, Akimoto T, Daiko H, Hamamoto Y, Matsushita H, Katano S, Hara H, Tanaka Y, Saito Y, Nagashima K, Igaki H.
    Int J Clin Oncol; 2019 Jan 15; 24(1):60-67. PubMed ID: 30109544
    [Abstract] [Full Text] [Related]

  • 9. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY, Hsu CP, Yeh HL, Chuang CY, Lin JF, Chang CF.
    Kaohsiung J Med Sci; 2018 May 15; 34(5):281-289. PubMed ID: 29699635
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
    Tahara M, Fuse N, Mizusawa J, Sato A, Nihei K, Kanato K, Kato K, Yamazaki K, Muro K, Takaishi H, Boku N, Ohtsu A.
    Cancer Sci; 2015 Oct 15; 106(10):1414-20. PubMed ID: 26250827
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.